409 related articles for article (PubMed ID: 9834817)
1. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
2. [Oxaliplatin: the first DACH platinum in clinical practice].
Soulié P; Raymond E; Brienza S; Cvitkovic E
Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Brienza S; Bensmaïne MA; Soulié P; Louvet C; Gamelin E; François E; Ducreux M; Marty M; André T; de Braud F; Bleiberg H; Ségal V; Itzhaki M; Cvitkovic E
Ann Oncol; 1999 Nov; 10(11):1311-6. PubMed ID: 10631458
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
Simpson D; Dunn C; Curran M; Goa KL
Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
Becouarn Y; Rougier P
Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
Wiseman LR; Adkins JC; Plosker GL; Goa KL
Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin clinical activity: a review.
Misset JL; Bleiberg H; Sutherland W; Bekradda M; Cvitkovic E
Crit Rev Oncol Hematol; 2000 Aug; 35(2):75-93. PubMed ID: 10936465
[TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
Bleiberg H
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
12. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
16. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Wasserman E; Sutherland W; Cvitkovic E
Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
[TBL] [Abstract][Full Text] [Related]
18. Current status of oxaliplatin in colorectal cancer.
O'Dwyer PJ; Johnson SW
Semin Oncol; 2003 Jun; 30(3 Suppl 6):78-87. PubMed ID: 12802798
[TBL] [Abstract][Full Text] [Related]
19. Ongoing and unsaid on oxaliplatin: the hope.
Cvitkovic E
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):8-11. PubMed ID: 9647613
[TBL] [Abstract][Full Text] [Related]
20. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
Chollet P; Bensmaïne MA; Brienza S; Deloche C; Curé H; Caillet H; Cvitkovic E
Ann Oncol; 1996 Dec; 7(10):1065-70. PubMed ID: 9037366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
